Published in Cancer Res on May 12, 2009
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun (2012) 1.36
Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol (2013) 1.21
Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal (2011) 1.04
Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. Carcinogenesis (2014) 0.91
Antagonistic pleiotropy at the human IL6 promoter confers genetic resilience to the pro-inflammatory effects of adverse social conditions in adolescence. Dev Psychol (2011) 0.90
Preliminary evidence of an association between an interleukin 6 promoter polymorphism and self-reported attentional function in oncology patients and their family caregivers. Biol Res Nurs (2013) 0.85
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. BMC Cancer (2014) 0.81
The associations between immunity-related genes and breast cancer prognosis in Korean women. PLoS One (2014) 0.81
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Sci Rep (2016) 0.79
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.79
Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia. Genet Test Mol Biomarkers (2014) 0.78
Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics (2012) 0.78
IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. BMC Cancer (2014) 0.76
IL-6 variant is associated with metastasis in breast cancer patients. PLoS One (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest (1998) 6.76
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem (2000) 3.03
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med (2003) 2.79
Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol (2005) 2.77
Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res (2000) 2.69
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol (2005) 2.30
Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res (1999) 2.17
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res (2001) 1.79
Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res (2001) 1.52
The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res (1999) 1.50
Efficient semiparametric estimation of haplotype-disease associations in case-cohort and nested case-control studies. Biostatistics (2006) 1.49
The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene (2001) 1.39
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res (2003) 1.35
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer (2002) 1.33
Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) (2001) 1.31
A gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol (2001) 1.29
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res (2005) 1.23
Haplotype-based association analysis in cohort studies of unrelated individuals. Genet Epidemiol (2004) 1.16
IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab (1995) 1.12
Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol (2007) 1.10
The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine (1998) 1.05
IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis (2001) 1.02
Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin Breast Cancer (2005) 0.97
Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med (2002) 0.95
Cytokine deregulation in cancer. Biomed Pharmacother (2001) 0.92
Control of aromatase activity in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol (1997) 0.88
Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. Biochim Biophys Acta (2004) 0.88
A novel single nucleotide polymorphism and five probable haplotypes in the 5' flanking region of the IL-6 gene in African-Americans. Genes Immun (1999) 0.86
Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer (2000) 0.86
Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer (2001) 0.85
An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology (2000) 0.83
Regulation of aromatase and sulphatase in breast tumour cells. J Endocrinol (1996) 0.80
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
How I treat extramedullary acute myeloid leukemia. Blood (2011) 3.42
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ (2002) 3.20
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol (2006) 2.92
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res (2008) 2.89
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res (2008) 2.81
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med (2003) 2.79
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J (2007) 2.65
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood (2004) 2.60
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol (2006) 2.46
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood (2008) 2.34
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol (2010) 2.31
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park) (2011) 2.25
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol (2009) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol (2013) 2.15
Provocative pearls in diagnosing and treating acute promyelocytic leukemia. Oncology (Williston Park) (2012) 2.13
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood (2013) 2.11
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood (2010) 2.05
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood (2007) 2.04
Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol (2007) 2.03
Acute myeloid leukemia. J Natl Compr Canc Netw (2012) 1.96
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood (2013) 1.87
Benchmarks in clinical productivity: a national comprehensive cancer network survey. J Oncol Pract (2007) 1.79
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol (2014) 1.79
Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics (2006) 1.77
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood (2006) 1.74
"Booster" training: evaluation of instructor-led bedside cardiopulmonary resuscitation skill training and automated corrective feedback to improve cardiopulmonary resuscitation compliance of Pediatric Basic Life Support providers during simulated cardiac arrest. Pediatr Crit Care Med (2011) 1.73
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res (2013) 1.70
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood (2009) 1.70
Focus on acute leukemias. Cancer Cell (2002) 1.67
Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev (2005) 1.66
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol (2006) 1.64
Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer (2006) 1.64
ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med (2011) 1.62
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood (2012) 1.61
Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol (2003) 1.59
A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials (2010) 1.59
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma (2014) 1.53
Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res (2008) 1.53
T-cell non-Hodgkin lymphoma. Blood (2005) 1.53
Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005. Pediatr Blood Cancer (2011) 1.52
Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. Am J Respir Crit Care Med (2014) 1.51
Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst (2005) 1.51
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol (2005) 1.51
Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma. Crit Care Med (2008) 1.50
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol (2003) 1.50
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma (2012) 1.49
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res (2004) 1.49
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol (2004) 1.48
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma (2014) 1.47
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res (2011) 1.44
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood (2006) 1.43